Brief: Irlab Provides Additional Efficacy Data From Phase IIb Study Of Pirepemat
28/03/2025 07:10
March 28 (Reuters) - IRLAB Therapeutics AB IRLABa.ST: IRLAB PROVIDES ADDITIONAL EFFICACY DATA FROM THE PHASE IIB STUDY OF PIREPEMAT IN PATIENTS WITH PARKINSON'S DISEASE IN MEDIUM PLASMA CONCENTRATION RANGE, PIREPEMAT REDUCED FALL RATE BY 51.5% AFTER THREE MONTHS OF TREATMENT Source text: ID:nMFN3876Qn Further company coverage: [IRLABa.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))